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Defining GC-specificity in the minor groove: side-by-side binding
of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G
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JW Lown3 and Richard E Dickerson1
Background: Polyamide drugs, such as netropsin, distamycin and their
lexitropsin derivatives, can be inserted into a narrow B-DNA minor groove to form
1:1 complexes that can distinguish AT base pairs from GC, but cannot detect
end-for-end base-pair reversals such as TA for AT. In contrast, 2:1 side-by-side
polyamide drug complexes potentially are capable of such discrimination.
Imidazole (Im) and pyrrole (Py) rings side-by-side read a GC base pair with the
Im ring recognizing the guanine side. But the reason for this specific G–Im
association is unclear because the guanine NH2 group sits in the center of the
groove. A 2:1 drug:DNA complex that presents Im at both ends of a GC base
pair should help unscramble the issue of imidazole reading specificity.
Results: We have determined the crystal structure of a 2:1 complex of a di-
imidazole lexitropsin (DIM), an analogue of distamycin, and a DNA decamer with
the sequence C-A-T-G-G-C-C-A-T-G. The two DIM molecules sit antiparallel to
one another in a broad minor groove, with their cationic tails widely separated.
Im rings of one drug molecule stack against amide groups of the other. DIM1
rests against nucleotides C7A8T9G10 of strand 1 of the helix, whereas DIM2
rests against G14G15C16C17 on strand 2. All DIM amide nitrogens donate
hydrogen bonds to N and O atoms on the floor of the DNA groove and, in
addition, the two Im rings on DIM2 accept hydrogen bonds from guanine N2
amines, thereby providing specific reading. The guanine N2 amine can bond to
Im on its own side of the groove, but not on the cytosine side, because of limits
on close approach of the two Im rings and the geometry of sp2 hybridization
about the amide nitrogen.
Conclusions: Im and Py rings distinguish AT from GC base pairs because of
steric factors involving the bulk of the guanine amine, and the ability of Im to
form a hydrogen bond with the amine. Side-by-side Im and Py rings differentiate
GC from CG base pairs because of tight steric contacts and sp2 hybridization
at the amine nitrogen atom, with the favored conformations being G/Im,Py/C
and C/Py,Im/G. Discrimination between AT and TA base pairs may be possible
using bulkier rings, such as thiazole to select the A end of the base pair. 
Introduction
1:1 and 2:1 minor groove binding drugs — incomplete
specificity
B-DNA minor groove binding drugs, such as the
polyamide drugs netropsin and distamycin (Figure 1),
have more potential for recognizing defined base
sequences than do intercalators, which insert flat organic
rings between base pairs adjacent to them. This is because
the intercalators essentially ‘see’ only the base pairs adja-
cent to them, whereas the groove-binding drugs can
extend for many steps along the floor of the groove.
Netropsin, distamycin and other chemically unrelated
minor groove binders share four common properties — an
overall flat molecule of thickness comparable to that of an
organic ring (but twisted at single bonds); a crescent shape
that helps it fit along the floor of the groove; hydrogen-
bond donors along the concave edge of the crescent, avail-
able to form bonds with N and O atoms on base edges;
and an overall positive charge, complementary with the
negative charge of the target DNA. Virtually all of these
groove-binding drugs are specific for AT regions of the
minor groove, and avoid regions of GC base pairs.
The first X-ray structure of a groove-binding drug in
complex with DNA, that of netropsin with C-G-C-G-A-A-
T-T-C-G-C-G [1–3], showed the basis for this AT-speci-
ficity. Firstly, the reading of AT-base pairs is accom-
plished by means of non-bonded contacts between the C2
hydrogen on adenine and the netropsin pyrrole CH or
methylene groups. Secondly, because an AT base pair has
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only two hydrogen bonds, it can twist or propeller more
than a GC pair with three such bonds. Propeller twisting
narrows the groove by shifting the positions of C1′ atoms
(see Figure 9 of [4]), producing a narrow groove that is
hospitable to a planar drug molecule. Thirdly, the ab-
sence of an N2 amine group on adenine makes the groove
deeper; conversely, the guanine amine tends to push the
drug away. Finally, the electrostatic potential well is
deeper in AT regions of the minor groove than in GC
regions, probably because of the absence of this same
amine group [5–7]. Hence, a cationic drug is more strongly
attracted to AT regions. 
Both netropsin and distamycin can be regarded as
polypeptide chains in which each alpha carbon has been
replaced by a five-membered pyrrole ring. The repeat dis-
tance in such an augmented polypeptide chain is almost
the same as the distance from one base pair to the next
along the floor of a B-DNA minor groove (but not quite;
see [8]). Hence, both the Lown group in Alberta and the
Dickerson group at UCLA simultaneously conceived the
idea of ‘lexitropsins’ — longer chain analogues of
netropsin which retain pyrrole groups at those positions
where an AT base pair was to be read, but substitute imi-
dazole groups at sites where GC base pair reading was
desired [1,9]. Imidazole, it was argued, would both
provide room for a guanine amine group and provide an
acceptor for a new hydrogen bond (see Figure 5 of [1]).
Initial lexitropsins with positive charges at both ends like
netropsin were nonspecific rather than GC-specific; elec-
trostatic attraction appeared to overwhelm purely steric
factors [9–12]. Monocationic lexitropsins based on a parent
distamycin proved more promising in recognition of GC
regions [13–15]. But it was still impossible to discriminate
between end-for-end reversals (such as AT for TA) of
either an AT or a GC base pair. The drug occupies the
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Figure 1
Molecular structure and nomenclature of
netropsin, distamycin and two lexitropsin
derivatives. Shorthand designations below
names are explained in text. Rings and amide
groups are numbered separately from left to
right, the conventional –NH–(Py/Im)–CO–
‘forward’ direction of the polypeptide
backbone. Note that 2-imidazole netropsin
differs from distamycin by substitution of
imidazole (l) for pyrrole (l) at ring number 1,
and by the absence of a leading amide group
(=). All four have a cationic tail (+), but only
netropsin also has a cationic head group at its
left end.
center of the narrow minor groove, and patterns of minor
groove hydrogen-bond donors and acceptors on either
base pair also are little changed upon reversal of the
pair — AT for TA and GC for CG (Figure 2). At best
these minor groove binders had the potential of reading
only half the information in the minor groove, and were
not even doing that very well.
The field was changed radically when Pelton and
Wemmer demonstrated by NMR techniques that, at suffi-
ciently high drug to DNA ratios, two distamycin mol-
ecules could sit side-by-side within a widened minor
groove [16–19]. Both AT and GC regions can be used,
given the proper drug analogues. GC regions are already
almost wide enough for side-by-side binding, and nor-
mally narrow AT regions are flexible enough to open to
the requisite width. Each drug molecule in a side-by-side
complex in effect reads one strand of the DNA duplex.
Hence, these side-by-side complexes have now raised the
possibility, not only of distinguishing AT from GC base
pairs, but of discriminating between end-for-end inver-
sions of a given base pair — AT versus TA and GC versus
CG. The full sequence information of the B-DNA duplex
may be available for readout through the minor groove.
The geometry of side-by-side binding
Both the original NMR and subsequent X-ray crystallogra-
phy studies [20,21] revealed several important principles
for side-by-side binding of distamycin and its lexitropsin
relatives. These are illustrated in Figure 3 by the di-imida-
zole lexitropsin bound to C-A-T-G-G-C-C-A-T-G, which is
the subject of this paper: 
1. Only monocationic drugs can form 2:1 side-by-side
complexes, and these molecules are staggered so as to
place their cationic tails far from one another. Dicationic
netropsin analogues do not form 2:1 complexes, presum-
ably because of charge repulsion between adjacent tails.
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Figure 2
Superposition of TA on AT and CG on GC
base pairs on their C1′ atoms. The upper
edge of each base pair builds the major
groove and the lower edge builds the minor
groove. Black dots are sugar C1′ atoms, small
open circles are nitrogens, large open circles
are oxygens and * = thymine methyl. (a) AT
base pair (solid bonds) superimposed on TA
(open bonds). (b) GC (solid) over CG (open).
Arrowheads point to O and N hydrogen-bond
acceptors and away from –NH2 hydrogen-
bond donors, as observed by Seeman et al. in
1976 [57]. Note that hydrogen-bonding
positions in the minor groove nearly coincide
following base pair reversal, making it
intrinsically difficult to detect base pair
reversals via minor groove ligands. In contrast,
hydrogen-bond donors and acceptors and the
thymine methyl in the major groove occupy
radically different positions following base pair
reversal, permitting easy discrimination of
base pair orientation by major groove probes. 
2. The –NH–(Py/Im)–CO–... direction from left to right, in
each of the drug drawings of Figure 1, follows the 5′ to 3′
direction of the oligonucleotide chain with which it makes
closer contact. That is, the formal ‘forward’ directions of
polypeptide drug and DNA chains happen to be the same.
3. Within the reference frame of the two side-by-side
polyamide drugs, stacking of one drug on the other is
always ring-upon-amide, never ring-upon-ring. Each
polarizable five-membered ring prefers to stack over the
polar NH and CO groups of a neighboring amide link.
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Figure 3
Stereo views of the complex of the di-
imidazole lexitropsin, oIm–Im+ or = l = l = +,
in a 2:1 complex with C-A-T-G-G-C-C-A-T-G.
Minor groove filled with two drug molecules
below; empty major groove above. (a) DNA is
shown in yellow stick bonds, with red bonds
for the two guanine nucleosides that are
specifically recognized by the drug. Two drug
molecules are stacked in opposite directions
down the groove, with O shown in red,
C in dark blue and N in light blue. Note how
the imidazole rings of one drug stack against
amide groups of the other drug, not against
that drug’s imidazoles. (b) Skeletal drawing of
the complex from the same orientation,
showing base numbering. Green dashed lines
are close non-bonded van der Waals
contacts. Red dotted lines mark hydrogen
bonds, with extra emphasis on the two bonds
involving imidazole nitrogens. (These same
bonds are seen more clearly in Figure 5.)
Drug molecule DIM1 is to the right, packed
against the C7A8T9G10 region of helix
strand 1. DIM2 is to the left, packed against
the G14G15C16C17 region of strand 2. 
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This at first surprising finding is in fact quite consistent
with the ‘polar-on-polarizable’ stacking observed in crys-
tals of nucleic acid constituents [22], hydrophobic interiors
of proteins [23,24], aromatic molecules in general [25] and
oligonucleotides [26].
4. Because the minor groove runs at roughly a 40° angle to
the DNA helix axis, the ring-upon-amide stacking just
mentioned ensures that two drug rings sit next to one
another at approximately the level of each base pair.
Hence, a given base pair has a five-membered ring from
each drug molecule associated with it, although it must be
emphasized that these rings are not adjacent to one
another in the ring-on-amide stacking of one drug on its
neighbor. 
The proliferation of distamycin analogues employed in
side-by-side drug complexes, and a sometimes not
obvious chemical nomenclature, have made it useful to
define a chemical shorthand that identifies the drugs and
clarifies how they stack against one another, ring against
amide, and with bases of the DNA duplex. This shorthand
terminology is illustrated below the names of the four
drugs in Figure 1. The simplest representation merely
lists pyrrole versus imidazole rings in a forward direction
along the polypeptide chain, with + or o to indicate charged
or uncharged ends, respectively. A more detailed repre-
sentation symbolizes the pyrrole ring by an open ring, l,
imidazole by a filled ring, l, an amide by a double link, =,
and a cationic tail by +. Hence, two-ring di-cationic
netropsin is + =l =l = +, three-ring monocationic dis-
tamycin is =l =l =l = +, and the di-imidazole lex-
itropsin is = l = l = +.
The issue of presence or absence of a leading amide
requires a fifth principle, of equal weight to the four listed
above: A drug without the leading amide achieves
maximum stacking (and acceptable separation of positive
charges) in the manner shown below, with the first ring of
one drug molecule stacked over the final amide of its
neighbor.
l=l =l = +
+ =l =l = l
This is termed maximum overlap stacking. In contrast, if a
leading amide group is present, then the upper drug can
slide one step to the right, separating the cationic tails still
further, while preserving exactly the same number of ring-
upon-amide stackings, see below. This is designated as
one-residue stagger. 
= l =l =l = +
+ =l =l = l =
This difference in drug stacking behavior will have drastic
implications for any theory of base sequence recognition
by side-by-side drugs. Essentially two different ‘lan-
guages’ of sequence recognition apply, depending on
whether a leading amide group is present or not. 
The above typographic diagrams lend themselves to a
convenient shorthand representation of base recognition.
Because the minor groove in B-DNA is roughly at 40° to
the helix axis, an unrolled-cylinder ladder diagram of the
drug complex appears as at left of Figure 4. This diagram
illustrates all five of the principles enumerated earlier:
monocationic drugs with widely separated tails, same for-
ward direction for a drug backbone and its nearer DNA
strand, ring-upon-amide stacking of neighboring drugs,
two adjacent rings at each given base pair level and max-
imal overlap packing in the absence of a leading amide.
The ladder diagram of Figure 4, although informative, is
tedious to construct. But the typographic representation
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Figure 4
Unrolled-helix representation of drug binding
within the minor groove of B-DNA (left), along
with a convenient typographic representation
(right). l represents a pyrrole ring and l an
imidazole or in some cases it represents a
pyridine ring in the first position. An
–CO–NH– amide is represented as = and +
is a positively charged tail. Diagonal lines in
typographic representation (right) indicate the
plane of base pairs, and the helix axis is
normal to these.
of drug packing that we have just seen can be turned into
the equivalent of a helix ladder diagram, rotated so the
minor groove direction is along the line of type, as at
right in Figure 4 where the lexitropsin oIm–Py–Py+,
without a leading amide is schematized. Here, the diago-
nal lines of the typographic representation serve as a
reminder of the plane of the base pairs. One base, two
associated drug rings and the complementary base lie
along a diagonal line from upper left to lower right, as in
the second base pair from the left which would be read
as G/Im,Py/C.
The code for DNA sequence recognition
Lown, Wemmer and collaborators have studied a 
series of lexitropsins, such as 2-imidazole-distamycin
= l = l = l = + [27,28] and cross-linked dimers
[29–32], all with a leading amide. In contrast, Dervan and
coworkers at Caltech have synthesized lexitropsins
without a leading amide, including 2-ImN (Figure 1) and
an analogue, 2-PyN, in which the first ring is a six-mem-
bered pyridine instead of five-membered imidazole
[33–38]. Both of these drugs can be represented conve-
niently by l = l = l = +. (The compounds 2-ImD, 2-
ImN and 2-PyN illustrate the confusion in current
nomenclature. In one convention, the ‘2’ indicates the
position in the drug of the imidazole ring; in the other
convention, the ‘2’ describes the C2 attachment to the
initial 5-membered ring.) From this work has come a
code for reading DNA base pairs by side-by-side drugs
[39,40]: firstly, Im and Py rings side-by-side recognize a
GC base pair, with Im specifically selecting the guanine
side; secondly, two adjacent Py rings at a given base pair
recognize an AT or TA base pair without regard to end-
for-end orientation. Experiments by Hartley and cowork-
ers on GC base recognition [15], as well as this work,
suggest yet a third line to the code — two adjacent Im
rings recognize a GC or CG base pair without regard to
orientation. This augmented code is shown in Table 1.
The association of pyrrole with AT base pairs and imida-
zole with GC pairs is sterically understandable, given
earlier experience with polyamide lexitropsins in 1:1
drug:DNA complexes [1,2,9]. But why should the imida-
zole of an Im,Py pair necessarily go to the side with
guanine? Because the guanine amine sits in the center of
the groove, could it not form a hydrogen bond with an imi-
dazole ring positioned to either its left or its right? To help
shed light on these questions, we have examined the
crystal structure of a monocationic di-imidazole lex-
itropsin, = l = l = +, with the DNA decamer C-A-T-G-
G-C-C-A-T-G, and observed it to bind in the following
manner:
Results and discussion
Drug–DNA Interactions
The complex of = l = l = + with C-A-T-G-G-C-C-A-T-
G was crystallized and found to be isomorphous with the
parent DNA, not in complex with the drug [41]. The
crystal structure was solved by molecular replacement, as
outlined in Materials and methods. The final refined
structure of the 2:1 drug:DNA complex is shown in
Figure 3. The complex obeys all five of the principles
enunciated earlier — it is a monocationic polyamide drug,
drug and nearer DNA chain run in the same direction,
ring-upon-amide stacking occurs between drug molecules,
drug rings are paired approximately at base pairs and a
one-residue stagger in drug packing occurs because of the
presence of a leading amide. 
Each drug molecule interacts primarily with one backbone
chain of the DNA helix, di-imidazole 1 (DIM1) with bases
C7A8T9G10 on the first strand of helix and DIM2 with
bases G14G15C16C17 on the second strand. NMR analysis
of a 1:1 complex between the di-imadazole and the same
DNA sequence [42] found the binding region to be
C6C7A8T9, a one-base shift from the DIM1 site observed
by X-ray diffraction. Figure 5 shows a close up of each
drug–DNA interaction, with the DIM1 diagram inverted
to place it in the same relative orientation as DIM2. All
drug–DNA distances of 3.5 Å or less are listed in Table 2,
along with a few longer values needed to maintain the
symmetry of DIM1 versus DIM2 binding. 
The first observation is that each polyamide makes intimate
van der Waals contacts with one wall of the minor groove.
As listed in Table 2 and seen in Figure 5, each sugar O4′
bridges amide and Im nitrogens, in a zig-zag pattern of close
contacts. Although these contribute much to the stability of
the complex, they make no contribution to its specificity.
All of the drug–DNA hydrogen bonds of a 1:1 complex are
retained in this 2:1 complex, but divided equally between
the two drug molecules. One can think of creating a 2:1
complex by cutting the drug molecule of a 1:1 complex in
half lengthwise, pushing each half toward one of the DNA
backbone chains (Figure 6) and shifting it a quarter base
pair repeat distance towards the 3′ end of its DNA strand.
The same bonds are formed with base edge N or O atoms.
But now the bifurcated bonds of the 1:1 complex (labeled
a–f in Figure 6a) are replaced by separate sets of bonds from
the two drug molecules (a–f in Figure 6b and Table 2).
Two other hydrogen bonds (g and h) are present from the
amine groups on guanines 14 and 15 to the two imidazole
rings on DIM2, and it is these bonds that establish the GC
versus AT specificity of binding. Two further hydrogen
bonds connect the amidinium tails of the drugs to DNA. 
Base specificity: AT/TA versus GC/CG
Of the four factors that are invoked to account for AT-
specificity in 1:1 groove-binding complexes — van der
C A T G G C C A T G
C T A C C G G T A C
= = =+
= =+=
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Waals contacts, groove depth, groove width and electro-
statics — the first two factors remain most relevant for 2:1
complexes. Pyrrole rings favor AT base pairs, because, in
making van der Waals contact with the floor of the
groove, the extra bulk of the ring C–H demands the
empty space provided by the absence of an N2 amine.
Conversely, imidazole rings favor GC base pairs because
their ring N atom provides both space for the guanine
amine and an acceptor for a new hydrogen bond from it
[1,9]. The guanine N2 is the only hydrogen bond donor in
the minor groove. 
Base specificity: GC versus CG
If the N2 amine nitrogen of guanine truly sits in the
center of the minor groove, then why should it not be able
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Table 1
Sequence recognition in the minor groove by side-by-side
polyamide lexitropsins.
Rings side-by-side Base pair read
Original scheme Im, Py G–C
Py, Im C–G
Py, Py A–T or T–A
Im, Im G–C or C–G
Proposed scheme Im, Py G–C
Py, Im C–G
Th, Py* A–T
Py, Th* T–A
*Th is thiazole.
Figure 5
Closeup views of single strand recognition by
individual lexitropsin molecules. Hydrogen
bonds and van der Waals interactions as in
Figure 3b. (a) Sequence-specific reading of
G14G15C16C17 by DIM2. Orientation as in
Figure 3. Backbone chain runs from G14 at
lower left to A18 at upper right. (b)
Nonspecific reading of C7A8T9G10 by DIM1.
View of Figure 3b is inverted to place
backbone and drug in comparable
orientations to (a). Backbone chain runs from
C7 at lower left to G10 at upper right. In both
drug molecules, each amide NH is hydrogen
bonded (thin red dashed lines) to a N or O on
a base edge. Each imidazole N in (a) is
hydrogen bonded to a guanine amine (thick
red dashed lines) and also packed in close
contact against the O4′ of a sugar ring. In (b),
imidazole hydrogen bonds are replaced by
van der Waals contacts (green dashed lines)
and the stacking of drug rings against sugar
rings is less orderly. Nitrogen atoms in the
drug are colored in blue.
(a)
(b)
to bind an Im from either side of the groove? The present
DIM–DNA structure was designed to bring two Im rings
into contact with the same GC base pair — one hydrogen
bonded specifically to the guanine amine, the other inter-
acting nonspecifically with cytosine. Figure 7 suggests
that this specificity involves a combination of stereochem-
istry and bond distances. The closest approach of the two
imidazole rings to the GC base pair is controlled by two
flanking hydrogen bonds from drug NH groups to ring
acceptors — a 2.80 Å N–N separation between the DIM2
NH and guanine N3 (labeled d in Figure 7) and a 2.94 Å
N–O separation between the DIM1 NH and cytosine O2
(labeled a in Figure 7). These bonds position the two drug
rings relative to the GC base pair.
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Figure 6
Unrolled ladder schematics of netropsin and
di-imidazole lexitropsin. (a) Netropsin in its 1:1
complex with C-G-C-G-A-A-T-T-C-G-C-G
[1–3]. (b) Di-imidazole lexitropsin in its 2:1
complex with C-A-T-G-G-C-C-A-T-G (this
work). Hydrogen bonds are indicated by
dotted lines, and their lengths for di-imidazole
lexitropsin are given in Table 2. Netropsin
bond lengths in Å are a = 3.3, b = 3.5,
c = 2.6, d = 2.6, e = 3.2 and f = 2.8. In both
this structure and the 2:1 distamycin
complexes with I-C-I-C-I-C-I-C [20,21], one
further refinement of the model is necessary.
Each drug molecule is pushed ‘downstream’
along its DNA strand by roughly one quarter
of a base pair repeat, in a direction that
shortens hydrogen bonds from drug amides
to base pair N and O. It remains true,
however, that a base pair has associated with
it one ring from each drug molecule, as the
central G14/Im,Im/C7 shown here. 
Table 2
Hydrogen bond and van der Waals distances between drug atoms and DNA.
DIM1 with DNA Bond distance DIM2 with DNA Bond distance
Drug atom strand 1 (Å) strand 2 (Å)
Carbonyl O1 C7–sugar O4′ 3.32 G14–sugar O4′ (3.68)
Amide 1-N C7–sugar O4′ 3.47 G14–sugar O4′ 3.28
Amide 1-N A8–sugar O4′ (3.54) G15–sugar O4′ 3.40
Im 1-N A8–sugar O4′ 2.99 G15–sugar O4′ 3.04
Amide 2-N T9–sugar O4′ 3.43 C16–sugar O4′ (3.51)
Im 2-N T9–sugar O4′ (3.55) C16–sugar O4′ 3.19
Amide 3-N G10–sugar O4′ 3.41 C17–sugar O4′ (> 4.0)
Amide 1-N C7–O2 2.94 a G14–N3 2.80    d
Im 1-N C7–O2 3.45 G14–N3 3.42
[G14–N2 3.46 i] G14–N2 3.21    g
A8–N3 3.44 G15–N3 (3.61)
Amide 2-N A8–N3 3.28    b G15–N3 3.30    e
Im 2-N A8–N3 (3.62) G15–N3 (3.66)
G15–N2 2.97    h
T9–O2 3.23 C16–O2 (3.92)
Amide 3-N T9–O2 2.88    c C16–O2 2.92    f
Amidinium G10–N2 3.02
A12–N3 2.59 C17–O2 2.58
A12–O4′ 3.46 A18–O4′ 3.28
Distances greater than 3.5 Å are included in parentheses, especially in
cases where the equivalent distance relating to the other drug
molecule is short. One cross-chain distance is given in square
brackets. Hydrogen bonds are in bold. Small letters identify bonds
labeled in stereo figures. 
The guanine amine N2 is delocalized into the aromatic
ring system with sp2 hybridization. The 120° bond geome-
try of sp2 hybridization points one hydrogen atom directly
at the cytosine O2 to which it is hydrogen bonded and the
other hydrogen directly toward the imidazole N of DIM2.
There is no inevitable reason why X–H...X hydrogen bonds
must be linear, because hydrogen bonds contain more of a
polar than a covalent character, and indeed many hydrogen
bonds exhibit X–H...X angles of as little as 92° [43]. But
distance arguments are more compelling. Because of posi-
tioning hydrogen bonds a and d in Figure 7, the ring nitro-
gen of DIM1 is held 3.46 Å away from the guanine N atom,
whereas the equivalent nitrogen of DIM2 can come to
within 3.21 Å of the guanine nitrogen. More to the point, if
a 1.0 Å N–H distance is assumed, then the hydrogen atom
available for hydrogen bonding is 2.2 Å away from the N of
DIM2 and a full 3.2 Å away from N of DIM1. The former
distance is somewhat long but not unheard of for a hydro-
gen bond; the latter is out of range [43]. Hence, an imida-
zole at the guanine end of the base pair forms a hydrogen
bond with the guanine amine, whereas an imidazole on the
cytosine end cannot get close enough. 
Base specificity: AT versus TA
The recognition code in its present form does not differen-
tiate between the two end-for-end orientations of an AT
base pair. Is there any hope of expanding the code to dif-
ferentiate AT from TA? A look at the minor groove in
Figure 2 shows that the pyrimidine O2 atom extends far-
ther into the minor groove than the purine N3 atom.
Indeed, this behavior of O2 versus N3 is also visible in
Figure 7; if the guanine amine is deleted, then the geome-
try of the purine–pyrimidine pair allows closer approach on
the purine side. This suggests that thymine might be
repelled systematically by increasing the bulk of the ring
in contact with it, causing the bulkier ring to favor ade-
nine. Hence, an expanded recognition code would add:
T/Py,X/A                    A/X,Py/T
where X represents the new and larger ring. The bulk of
the contacting five-membered ring could be enhanced by
replacing the pyrrole contact CH with CH2 (as in cyclo-
pentadiene), S (in thiophene or thiazole), C = O (cyclo-
pentanone or cyclopentenone) or methyl, C–CH3. It is
true that an added methyl group may be too large, and
ketones may be too reactive. Chemical synthesis and foot-
printing analyses will be needed to test this. But Lown
and coworkers have already carried out studies using thia-
zole lexitropsins, which direct a sulfur atom toward the
floor of the groove [44]. They report that thiazole lex-
itropsins ‘exhibit strict preference for AT sequences and
are even more discriminating than distamycin’. Perhaps a
side-by-side pairing of pyrrole with thiazole is a good point
of departure for footprinting experiments. 
The desired AT versus TA selectivity is demonstrated by
the TATA-binding protein or TBP, which discriminates
between TA and AT at the first base pair of eight in the
TATA box, but not at the eighth base pair [45]. The first
position is very influential in determining the suitability of
a sequence as a functioning TATA box. Wobbe and Struhl
[46] have exhaustively examined point mutations of the
TATA sequence, T-A-T-A-A-A, and found that reversal
of the first base pair, yielding A-A-T-A-A-A, reduces in
vitro activity to 30–33% in both HeLa and yeast cell
assays. At the first base pair of the TATA box (Figure 5 of
[45]). TBP pushes a proline sidechain snugly up against
the N3 atom on the adenine side of the base pair. Model-
ing of reversal of the TA pair indicates that the O2 atom of
thymine would exhibit a mild steric clash with proline,
disfavoring the reversed orientation. It has been shown
recently that TBP–TATA box complexes can be induced
to crystallize with the ‘wrong’ base, T, G or C, at the criti-
cal first base pair recognition locus on the second strand
(SK Burley, personal communication). The protein simply
adjusts slightly to make room. But the question is, at what
cost in free energy? A protein is inherently elastic, not
rigid. Even a modest free energy difference could produce
the kind of selectivity that is observed by Wobbe and
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Figure 7
Structural basis for the ability of imidazole to discriminate between GC
and CG base pairs. Imidazole rings from DIM2 (left) and DIM1 (right)
are held at fixed distances from the GC base pair. DIM2 can sense the
presence of guanine via an hydrogen bond (g) to the N2 amine of
guanine 14, one of whose H atoms points directly at the imidazole by
virtue of sp2 hybridization at the amine nitrogen. DIM1, on the other
side of the minor groove, is farther from the N2 atom, and is badly
oriented relative to the amine hydrogens. Critical N–N distances in Å
from Table 2 are g = 3.21, i = 3.46, d = 2.80 and a = 2.94.
Struhl [46]. Substitution of G for the initial T is even more
catastrophic. To the injury of pyrimidine at the proline
locus then is added the insult of an amine in the center of
the groove, and activity falls to 5–8%.
If the foregoing proposal for AT discrimination proves
valid in tests now under way, then the complete base-
reading code can be summarized as: 
G/Im,Py/C     C/Py,Im/G        A/Th,Py/T        T/Py,Th/A
where Th represents thiazole or one of the other bulky
groups described in the previous section. Considering the
paired pyrroles of side-by-side distamycins as a starting
point, replacement of one pyrrole by thiazole would pro-
duce orientation-specific AT recognition, just as replace-
ment of one pyrrole by imidazole produces orientation-
specific GC recognition. 
The two coding ‘languages’
As mentioned earlier, the relative alignment of two side-
by-side drugs depends very much on whether or not they
possess a leading amide. The only other X-ray crystal
structure analyses to date of 2:1 side-by-side complexes
involve inosine–cytosine (IC) base pairs, which in this
context behave like AT pairs [20,21]. The complex of dis-
tamycin with (I–C)4 has the structure:
This complex, as does ours, exhibits the one-residue
stagger expected for a drug bearing a leading amide group.
Yet the sequence recognition trials reported by Dervan
and coworkers demand what is termed maximum overlap.
Hence, two ‘dialects’ of the recognition code exist, which
are controlled by regulating the overlap of side-by-side
drug molecules. The four ring oIm–Im–Py–Py+, for
example, would read the base sequence G-G-C-C without
a leading amide, but would read x-G-%-C-x (where x is
any base and % is a GC base without regard to orientation)
if a leading amide is present:
In sum, it is essential to control the relative alignment of
two drugs when designing sequence-specific side-by-side
agents. One vehicle, of course, is the leading amide group
just mentioned. A second positioning agent is bis-linkages
or tethers across the two drug molecules, as have been
exploited both by Lown [29–32] and by Dervan [36,39]. A
third and more radical approach is that of synthesizing
longer molecules with flexible ‘joints’, that will fold back
into hairpins to bring the correct rings into contact [47–51]
Studies by both the Lown and Dervan groups indicate an
increase in binding affinity of up to two orders of magni-
tude for side-by-side linked drugs using either hairpins or
methylene tethers [29,47,52]. For hairpins with γ-amino-
butyric acid linkers, Walker et al. [53] have proposed a
mathematical model for estimating the free energies of
binding to various DNA sequences. In another study [54],
they have designed optimal geometries for linkers
between two side-by-side polyamides using not only
methylenes, but other heteroatoms in the linking chain. A
novel hydrogen bond ‘zipper’ to hold the side-by-side
ligands together has also been designed (see Figure 5 of
[54]). The ‘zipper’ consists of a row of hydrogen bonds
between carbonyl oxygens on one drug molecule and
hydroxymethyl groups on the rings of the second. 
Once the relative positioning of rings in the side-by-side
drug pair has been fixed, then the code or an extension of
it can be used to read pre-selected DNA sequences.
Although reading at present is not exhaustive, past experi-
ence with thiazole rings and analogies with end-for-end
recognition of the TATA box suggest a way of expanding
the code toward complete discrimination of GC, CG, AT
and TA base pairs.
Biological implications
1:1 complexes between DNA and minor groove binding
drugs, such as netropsin, distamycin and their lex-
itropsin derivatives, can distinguish AT base pairs from
GC, but not end-for-end base-pair reversals — AT for
TA, or GC for CG. Hence, they can read half the infor-
mation present in the minor groove. But side-by-side
binding of two drugs within a widened minor groove
offers a potential for greater discrimination, because
each drug effectively reads one side of the groove, or one
strand of the helix.
The parent compounds, netropsin and distamycin, can
be regarded as polyamide or polypeptide chains in which
each alpha carbon is replaced by a pyrrole (Py) ring.
Lexitropsins are longer chain polyamide analogues in
which one or more pyrroles are replaced by imidazoles
(Im). Two pyrrole rings side-by-side across the minor
groove favor AT or TA base pairs over GC base pairs,
because of space constraints placed by the N2 amine
group on guanine. An imidazole and a pyrrole packed
side-by-side favor a GC base pair, with G on the imida-
zole side, because of hydrogen bonding from the guanine
amine to the imidazole ring nitrogen. Hence, GC can be
differentiated from CG by the proper arrangement of
imidazole and pyrrole rings.
It is proposed that end-for-end discrimination in AT
base pairs might be provided by means of a still bulkier
thiazole (Th) ring, which would prefer the A end of an
Maximum overlap:
G G C C
C C G G
= = = =+
= = =+=
One base stagger:
x G % C x
x C % G x
== = = =+
= = = =+=

I C I C I C I C
C I C I C I C I
= = = =+
= = =+=
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AT base pair. Hence, the complete sequence-reading
code for the minor groove would be:
G/Im,Py/C      C/Py,Im/G        A/Th,Py/T      T/Py,Th/A
As the ring-plus-amide repeat length along the drug is
roughly comparable with the distance from one base
pair to another along the floor of the minor groove,
extended side-by-side lexitropsins may permit binding
selectively and specifically to a pre-chosen DNA
sequence. This can be potentially useful to vector a drug
for a specific target in chemotherapy, to probe genomic
DNA to locate specific sequences, and, with the addition
of molecular scissors, becomes a useful tool for gene
therapy.
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Figure 8
Difference maps and drug positioning. (a)
(Fo–Fc) map of DIM1 on strand 1, contoured
at 1.2σ. (b) (Fo–Fc) map of DIM2 on strand 2,
contoured at 1.2σ. These were the first
difference maps on which the entire drug
molecule — three-ring core and flexible tail —
was clearly defined. 
Materials and methods
The di-imidazole lexitropsin (DIM) was synthesized in the laboratory of
JW Lown of Alberta, Canada, and the DNA decamer CATGGCCATG
was synthesized at UCLA by the solid phase phosphoramidite method.
2:1 drug:DNA crystals were grown at 4°C by vapor diffusion in a sitting
drop containing 0.45 mM duplex DNA, 0.90 mM DIM, 12 mM CaCl2,
7 mM spermine hydrochloride (pH 7.0) and 15% (v/v) 2-methyl-2,4-
pentanediol (MPD) against a reservoir of 45% MPD. After 3 months,
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Figure 9
Difference maps and drug positioning. (a)
Final (2Fo–Fc) map after refinement of DIM1
on strand 1, contoured at 0.9σ. (b) Final
refined (2Fo–Fc) map of DIM2 on strand 2,
contoured at 0.9σ.
crystals appeared as long rods (2.75 mm × 0.25 mm × 0.20 mm). They
were mounted in a glass capillary for data collection at 5°C on a Rigaku
R-Axis II Image Plate.
DIM/DNA crystals were isomorphous with native CATGGCCATG [41],
crystallizing in space group P212121 with cell dimensions a = 36.654 Å,
b = 42.643 Å, c = 34.684 Å, and diffracted to 1.8 Å. The structure was
solved by molecular replacement with XPLOR [55], using as the starting
model an ideal CATGGCCATG helix fitted onto the CATGGCCATG
coordinates for proper placement in the cell. Data collection and refine-
ment statistics are given in Table 3. 
Rigid body refinement from 8–3 Å was carried out in five stages
using five choices of rigid bodies: the entire double helix; each strand
singly, ten individual base pair dinucleotides, including phosphates
and sugars; twenty individual nucleotides; and sixty uncoupled bases,
sugars and phosphates. The starting R factor was 56.5%, dropping
to 42.0% after rigid body refinement. NUCLSQ positional and B-
refinement [56] followed, with the gradual addition of data to 1.8 Å.
43 solvent molecules were then added to improve the phases, and a
difference map indicated drug density next to C7A8T9G10. The three-
ring core of DIM1 could be placed unambiguously in the difference
map, and the more flexible tail density became clearer after further
refinement and difference maps. In a similar manner, the three-ring
core of DIM2 on strand 2 near G14G15C16C17 was positioned in the
difference map first, and its tail added to density after refinement.
Figures 8a and b show difference map images of both DIM1 and
DIM2 at the point where the entire skeleton of each molecule
became clear. Because the DIM2 difference density possessed some
ambiguity, two positions were refined for a number of cycles — that
drawn in Figure 8b, and a model with the drug shifted down the
density crescent by half a repeating unit. The choice with the lower R
factor was selected for continued refinement. Figures 9a and b
depict the final drug images after refinement.
Refinement continued with the addition of solvent and a hydrated
calcium ion. Water molecules were positioned where peaks greater
than 1σ appeared in (2Fo–Fc) maps and where peaks at least 3σ simul-
taneously appeared in (Fo–Fc) difference maps. With DNA (404
atoms), two drug molecules (26 atoms each), 58 water molecules and
one hydrated calcium ion, the final 1σ R factor was 20.0%. 
Accession numbers
Original Fo data and final coordinates have both been deposited in the
Nucleic Acid Data Bank (code GDJ054) and the Brookhaven Protein
Data Bank ( code 334D) and are available for immediate distribution.
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